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1. Introduction
Chan Su is a traditional Chinese medicine prepared 
from the dried white secretion of the auricular 
and skin glands of the toads Bufo bufo gargarizans 
Cantor or Bufo melanostictus Schneider [1]. The 
secretion commonly contains biogenic amines, al-
kaloids, peptides, proteins, and bufadienolides, one 
of the main components of Chan Su and a newly 
recognized type of natural steroids with potent 
bioactivities [2]. Chan Su has been used in the 
treatment of various diseases, including cancer, 
arrhythmia, and other heart diseases. Studies in vivo 
or in vitro have shown that HuaChanSu, an extract 
of a species of Chinese toad, has several functions, 
including the ability to kill several kinds of tumor 
cells, an antitumor effect, a leukopoietic effect, 
and increased immunity [3].
Unfortunately, HuaChanSu has obvious side ef-
fects in clinical settings because of serious toxicity 
to humans and, thus it had been used carefully 
by clinicians. Chan Su overdose can cause nausea, 
vomiting, diarrhea, and even general paralysis [4]. 
Toad toxin poisoning manifests primarily as digitalis 
toxicity-like cardiac effects, including bradycar-
dia, atrioventricular conduction block, ventricular 
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tachycardia, ventricular fibrillation, and sudden 
death [5]. The death of one Chinese woman after 
ingestion of a Chinese herbal tea containing Chan 
Su has been reported and a trial has been per-
formed regarding the lethality to mice of Chan Su 
in diverse consuming types [6]. One study reported 
the lethal dose causing 50% death (LD50) of toad 
skin extract in mice was ∼400 mg/kg intravenously 
[7]. We could not locate any systemic in vivo trials 
evaluating Chan Su’s toxicity and its no-observed-
adverse-effect-level (NOAEL).
Aqueous extracts of SB were administered orally 
to male Institute for Cancer Research (ICR) mice 
and the pathological changes observed. The present 
communication presents the results of this study 
and evaluates the toxicity of this SB extract in male 
ICR mice.
2. Materials and Methods
2.1. Test material
Solid powder of whole Secretio Bufonis (SB) ex-
tracts was obtained from Dunsan Oriental Hospital 
(Daejeon, South Korea). Fifty gram of SB was washed 
with distilled water, and then boiled with 80ºC for 
6 hours. Solid particles and aggregates were removed 
by centrifugation at 3000g for 30 minutes and the 
supernatant lyophilized. The resulting 22.5 g of 
lyophilized SB was stored at −20ºC until used.
2.2. Animals and administration method
Fifty male ICR mice (6 weeks old, Samtako, Korea) 
were used after acclimatization for 7 days. The 
animals were housed individually in suspended 
wire cages in a temperature (21−24oC) and humid-
ity (43−40%) controlled room with a 12:12 hour 
light:dark cycle and provided food (Pellet, Samyang, 
Korea) and water ad libitum. These mice were 
equally distributed into 10 groups (five groups for 
the short term toxicity study, five groups for a long 
term toxicity study). 
The expected, normal, human tolerance to SB is 
approximately < 0.5−1 mg/kg/day. Based on the use 
of SB in animal studies and clinical applications, 
dosages of 0, 0.05, 0.5, 5, and 50 mg/kg/day were 
set for the short term toxicity study and 0, 0.01, 
0.05, 0.25, and 0.5 mg/kg/day for the long term 
toxicity study. While the extract was orally admin-
istered to mice, distilled water was administered 
to the control group. The total volume administered 
was 0.15 mL/kg body weight. For the short term 
toxicity study, the groups were designated as fol-
lows: 0 mg/kg SB distilled water control group, D.W.; 
0.05 mg/kg SB, SB-S1; 0.5 mg/kg SB, SB-S2; 5 mg/kg 
SB, SB-S3; and 50 mg/kg SB, SB-S4. For the long term 
toxicity study, the groups were: 0 mg/kg SB distilled 
water control group, D.W.; 0.01 mg/kg SB, SB-R1; 
0.05 mg/kg SB, SB-R2; 0.25 mg/kg SB, SB-R3; and 
0.50 mg/kg SB, SB-R4.
Representative dose preparations for each SB 
concentration were analyzed for homogeneity of 
distribution, concentration, and stability during the 
studies. An appropriate amount of the test sub-
stance or distilled water was administered orally to 
each mouse for 1 week in the short term study, and 
8 weeks in the long term study. Mice were moni-
tored for mortality, signs of gross toxicity, and be-
havioral changes at least once daily for the duration 
of the studies. 
2.3.  Hematology, biochemistry parameters, 
and urine analysis
All mice were fasted ∼18 hours prior to collection 
a blood sample from the descending aorta under 
ether anesthesia at the termination of the experi-
ment. Urine analysis, including specific gravity, pH, 
leukocyte, nitrite, protein, glucose, ketone, uro-
bilinogen, bilirubin, and blood, was conducted using 
Bayer Diagnostics Multistix 10SG (Not. 5J06C, USA) 
REF 2300 (03536597) reagent strips for urine analy-
sis and a Urine Chemistry Analyzer (Bayer Clinitek 
500, USA). 
2.4. Morphologic pathology evaluations
In the long term study, complete post morphologic 
evaluations were immediately performed on mice 
found dead to avoid organ autolysis and, at the ter-
mination of the study, the surviving animals were 
fasted overnight, weighed, and humanely killed using 
anesthetic ether. 
Gross pathologic evaluations were performed and 
the weight of liver, kidney, heart, spleen, lungs, tes-
tis, and brain measured and recorded. The relative 
organ weights (organ to body weight ratio) were 
also calculated. Histopathological examination was 
performed on routinely prepared sections of hepatic 
and renal tissues; the tissues were fixed in 10% for-
malin immediately after removal and weighing and 
standard hematoxylin and eosin staining performed.
2.5. Statistics
The Mann-Whitney U-test was used to compare the 
homogeneity of variance in the numerical data (body 
weight, food and water consumption, hematology, 
blood chemistry, and organ weights). If there was 
homogeneity of variance in the data between groups, 
a one way ANOVA test was conducted. For these 
analyses, Microsoft Excel 2002 and SPSS 10.1 were 
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used and statistical significance was considered at 
p < 0.05. 
3. Results
3.1.  SB-consumption group in short term 
toxicity study showed significantly 
increased heart weight
Absolute and relative weights of treated mice indi-
cated that there were no statistically significant 
differences among the treated groups without con-
sidering relative heart weight. The relative heart 
weight of SB-S4 group mice was greater than that 
of the control group (p < 0.05) (Table 1).
3.2.  SB-consumption group in short term 
toxicity study showed higher values of 
AST as a biochemical parameter
The AST level in mice of the SB-S4 group was higher 
than in the control group (p < 0.05) (Table 2).
3.3.  SB-consumption group in long term 
toxicity study had a more significant 
absolute brain weight gain than the 
control group
Absolute and relative weights of treated mice indi-
cated that there were no statistically significant 
differences among treated groups without consider-
ing absolute brain weight. The absolute brain weight 
Table 1 Relative organ weights of mice with oral SB for 1 week
Group−Dose  Body weight Liver Kidney  Spleen Testis  Brain Lung Heart
(mg/kg/day)  (g) (%) Lt. (%) Rt. (%) (%) Lt. (%) Rt. (%) (%) (%) (%)
D.W. Mean 35.8 5.7 0.7 0.7 0.4 0.3 0.3 1.4 0.6 0.4
(0) SD 2.59 0.47 0.10 0.10 0.09 0.02 0.03 0.09 0.07 0.03
SB-S1 Mean 34.8 5.3 0.8 0.8 0.4 0.3 0.3 1.4 0.7 0.4
(0.05) SD 1.92 0.59 0.06 0.07 0.04 0.04 0.04 0.11 0.10 0.04
SB-S2 Mean 35.6 4.3 1.9 1.9 0.9 0.8 0.8 3.7 1.7 1.2
(0.5) SD 2.07 2.50 2.65 2.80 1.21 1.02 0.97 5.20 2.52 1.69
SB-S3 Mean 34.4 5.2 0.7 0.8 0.4 0.3 0.3 1.4 0.7 0.4
(5) SD 2.07 0.17 0.07 0.06 0.07 0.02 0.02 0.12 0.07 0.06
SB-S4 Mean 33.6 5.4 0.7 0.8 0.4 0.3 0.3 1.5 0.7 0.5*
(50) SD 2.07 0.70  0.08 0.06 0.06 0.02 0.03 0.08 0.06 0.04
Five mice/group; given SB in different concentrations for 1 week; organ weight and percentage to body weight; relative heart 
weight of SB-S4 larger than control group (0.5 ± 0.04%, p < 0.05). *Significantly different from values of D.W. group at p < 0.05. 
Lt. = left; Rt. = right; SD = Standard Deviation; D.W. = Dextrose water; SB-S = Secretio Bufonis short term toxicity group.
Table 2 Blood chemical values of mice with oral SB for 1 week
Group−Dose  Total Albumin A/G Creatinine BUN Total Triglycerides GOT GPT
  protein  ratio   cholesterol
(mg/kg/day)
  (g/dL) 
(g/dL)
 (g/dL) 
(mg/dL)
 
(mg/dL)
 (mg/dL) 
(mg/dL)
 
(U/L)
 
(U/L)
D.W. Mean 3.1 1.5 1.0 0.3 22.1 99.2 76.8 73.0 45.0
(0) SD 0.25 0.06 0.14 0.03 2.73 6.33 8.63 7.93 8.81
SB-S1 Mean 3.1 1.7 1.2 0.3 19.8 103.0 61.6 76.8 26.6
(0.05) SD 0.05 0.06 0.09 0.03 2.41 4.83 6.94 8.42 2.05
SB-S2 Mean 3.3 1.7 1.0 0.2 20.4 104.8 64.8 72.2 25.0
(0.5) SD 0.10 0.07 0.05 0.06 1.91 2.75 8.08 5.47 1.54
SB-S3 Mean 3.7 1.7 0.9 0.2 20.3 111.6 65.0 97.6 29.2
(5) SD 0.32 0.11 0.16 0.04 2.12 9.09 8.51 14.88 1.14
SB-S4 Mean 3.7 1.6 0.9 0.2 20.1 112.6 68.0 98.0* 27.4
(50) SD 0.29 0.07 0.18 0.02 1.50 11.25 7.66 7.52 3.91
GOT level in SB-S4 group higher than control group (98.0 ± 7.52%, p < 0.05). *Significantly different from values of D.W. group at 
p < 0.05. A/G = Albumin/Globulin ratio; BUN = blood urea nitrogen; GOT = Glutamic oxaloacetic transaminase; GPT = Glutamate 
pyruvate transaminase; SD = Standard Deviation; D.W. = Dextrose water; SB-S = Secretio Bufonis short term toxicity group.
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of SB-R4 group was significantly greater than the 
control group (p < 0.05) (Table 3).
3.4.  SB-consumption group in long term 
toxicity study had significantly lower 
values for creatinine and higher values 
of blood urea nitrogen (BUN) than the 
control group
No significant hematological changes attributable 
to SB after the dosing period were observed without 
considering the creatinine and BUN values (Table 4). 
A significantly lower value of creatinine was ob-
served in the SB-R1 and SB-R2 groups and higher 
values of BUN in the SB-R4 group.
4. Discussion
Toad venom contains two groups of toxic com-
pounds: steroid derivatives that resemble cardiac 
glycosides, consisting of bufagenins (bufagins and 
bufadienolides) and bufotoxins, and the basic com-
ponents that include epinephrine, norepinephrine, 
serotonin, and bufotenin [7]. These compounds have 
a narrow range between a treatment dose and a 
lethal dose.
Some people believe that microbial biotechnology 
can improve this supplement to produce or develop 
more therapeutic advantages, such as increased 
potency, longer half-life in the bloodstream, sim-
pler delivery methods, and reduced side effects [8]. 
Table 4 Blood chemical values of mice with oral SB for 8 weeks
Group−Dose  Total Albumin A/G Creatinine BUN Total TGs GOT GPT
  protein  ratio   cholesterol
(mg/kg/day)
  (g/dL) 
(g/dL)
 (g/dL) 
(mg/dL) (mg/dL)
 (mg/dL) 
(mg/dL) (U/L) (U/L)
D.W. Mean 4.8 2.3 0.9 0.4 21.5 93.0 144.4 78.2 28.8
(0) SD 0.16 0.05 0.02 0.06 1.33 4.06 27.29 11.35 7.65
SB-R1 Mean 4.6 2.1 0.9 0.2* 23.4 85.4 107.2 137.2 36.6
(0.01) SD 0.21 0.15 0.08 0.02 2.82 7.01 27.70 33.14 15.54
SB-R2 Mean 4.9 2.4 1.0 0.2* 20.6 105.2 87.2 74.8 15.0
(0.05) SD 0.19 0.05 0.05 0.06 1.18 6.17 10.28 4.16 2.60
SB-R3 Mean 4.6 2.3 1.0 0.4 20.6 99.0 111.0 114.4 16.4
(0.25) SD 0.12 0.06 0.09 0.02 1.50 10.42 9.77 22.62 1.79
SB-R4 Mean 4.6 2.2 1.0 0.4 26.3* 89.0 122.8 153.6 18.2
(0.50) SD 0.30 0.06 0.07 0.04 0.32 5.70 21.76 42.08 1.85
Significantly lower Creatinine level in SB-R1 and SB-R2; higher BUN level in SB-R4 group (0.2 ± 0.02%, 0.2 ± 0.06%, 26.3 ± 0.32%, 
respectively). *Significantly different from values of D.W. group at p < 0.05; A/G = Albumin/Globulin ratio; BUN = blood urea 
nitrogen; GOT = Glutamic oxaloacetic transaminase; GPT = Glutamate pyruvate transaminase; SD = Standard Deviation; D.W. = 
Dextrose water; SB-R = Secretio Bufonis long term toxicity group; TGs = triglycerides.
Table 3 Absolute organ weights of mice with oral SB for 8 weeks
Group−Dose  Body weight Liver Kidney  Spleen Testis  Brain Lung Heart
(mg/kg/day)  (g) (mg) Lt. (mg) Rt. (mg) (mg) Lt. (mg) Rt. (mg) (mg) (mg) (mg)
D.W. Mean 36.8 1634.6 233.0 223.8 101.6 112.8 108.4 491.0 176.8 135.8
(0) SD 2.95 177.41 28.95 31.74 16.27 8.67 6.88 14.54 14.99 8.32
SB-R1 Mean 34.0 1491.4 240.0 225.6 96.6 107.6 100.0 461.4 176.2 136.6
(0.01) SD 2.65 280.30 35.06 11.06 18.64 7.80 6.20 40.32 14.53 12.90
SB-R2 Mean 36.8 1562.4 231.8 220.2 96.4 111.2 107.2 479.2 179.4 141.0
(0.05) SD 2.59 251.09 36.54 33.97 13.90 18.16 10.73 39.19 25.31 14.23
SB-R3 Mean 33.0 1380.6 214.8 210.8 89.0 111.0 103.2 464.4 169.8 122.6
(0.25) SD 2.55 196.74 19.52 10.35 19.20 9.35 7.43 39.51 16.27 10.43
SB-R4 Mean 36.4 1485.2 240.8 230.6 99.0 113.4 106.4 460.8* 173.2 128.4
(0.50) SD 3.58 248.10 30.82 27.46 16.16 7.64 6.80 13.14 19.45 13.79
Larger brain weight in SB-R4 (460.8 ± 13.14%, p < 0.05). *Significantly different from values of D.W. group at p < 0.05. Lt. = left; 
Rt. = right; SD = Standard Deviation; D.W. = Dextrose water; SB-R = Secretio Bufonis long term toxicity group.
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New compounds have been found with greater cyto-
toxic activities in vitro than cinobufagin but their 
cytotoxicity have not been studied, and they have 
not been used in the clinical setting.
Here, we aimed to elucidate the oral toxicity 
of SB by preparing ICR mice in several groups and 
administering SB in a short term and a long term 
toxicity study. The dosages chosen were based on 
other available studies. 
In the short term study, the mice given SB at 
50 mg/kg/day showed greater increases in relative 
heart weight and higher AST activities than the other 
study groups. A heart usually grows larger as its cir-
culatory function grows weaker and the resulting 
cardiomegaly can induce myocardial infarction which 
leads to increases in AST secretion into the blood-
stream. The results here suggested that SB signifi-
cantly affected the mouse heart in 1 week with 
consumption over 50 mg/kg/day and, thus we con-
cluded that SB had significant toxicity in mouse heart 
under these conditions. On this basis, the NOAEL of SB 
for 1 week was considered to be under 5 mg/kg/day. 
In the long term toxicity study, the groups ad-
ministered SB at 0.5 mg/kg/day had larger absolute 
brain weight than the other groups. This increased 
brain weight could have some interesting implica-
tions, such as symptoms like autism or brain devel-
opment. Further studies, such as observations of the 
behavioral changes or brain imaging studies, are 
needed to determine the cause of this brain hyper-
trophy, as the use of normal mice here obviated the 
chance for the present results to be expressions of 
congenital malformations.
We also observed that 0.01 mg/kg/day-SB ad-
ministered mice and 0.05 mg/kg/day-SB adminis-
tered mice had lower creatinine concentrations in 
their blood. Plasma creatinine, which results from 
catabolism of creatine phosphate in skeletal mus-
cle, increases when renal function is poor and de-
creases with losses of skeletal muscle [9]. Lowering 
creatinine concentrations did not appear to be a 
useful evaluation factor of SB toxicity.
The BUN content in the mice administered SB 
in 0.5 mg/kg/day was higher than in other groups. 
BUN content usually increases when kidney filtra-
tion is failing or liver is compromised in some man-
ner. We suggest here that SB had toxicity to mouse 
liver when administered at doses over 0.5 mg/kg/
day for 8 weeks, indicated by the results of the 
long term study. Thus the NOAEL for an 8 week SB 
administration was considered to be less than 
0.25 mg/kg/day.
Some literature has reported that SB has syn-
ergistic therapeutic efficacy with some drugs in 
treating cancers [10]. Combination therapy could 
increase efficacy and improve patients’ quality of 
life significantly compared with chemotherapy alone 
[11]. Based on these results, one cancer center in 
the United States has been proceeding with phase 
I trials with a Chinese university since 2006 for 
evaluating the efficacy of HCS as measured by pro-
gression free survival over 4 months. In addition, 
randomized, placebo-controlled, blinded phase II 
studies of Huachansu and Gemcitabine in treating 
pancreatic cancer are in progress. 
SB toxicity is one of the major obstacles to its 
usage in cancer treatment. Although some research-
ers seek to find means to yield SB less toxic and 
more effective, we need to know the toxicity of SB 
itself due to its current use in clinic. Otherwise, it 
is not possible judge the dangers of SB is and plan 
the appropriate limited dosages.
Here, the results of short and long term studies 
of aqueous SB toxicity have provided a reliable 
means for judging SB for clinical use. It is notewor-
thy that SB did not pose any dangers in normal mice 
at less than 5 mg/kg/day for 1 week of oral intake 
and 0.25 mg/kg/day for an 8 week period. But, SB 
water extracts may induce heart and liver toxicity 
when used at higher than 5 mg/kg/day for 1 week 
and 0.5 mg/kg/day for 8 weeks.
These present studies encountered some prob-
lems regarding the exact toxicity of SB in that we 
only observed changes caused and did not further 
examined how or why the changes occurred. We 
relied on information retrieved from other studies 
and reports that correlate similar symptoms in dif-
ferent circumstances. Although we looked for ob-
servable changes in liver and kidney tissues, possible 
changes at the molecular level that could have 
been present were not addressed.
Despite these shortcomings, these studies were 
meaningful because of SB’s widespread usage and 
known effects, such as cardiotonic effects caused by 
toad skin extracts. The widespread assumption that 
toad skin extracts pose some dangers to the cardio-
vascular system was strengthened by the present 
results. However, SB has great possibilities as an 
effective antitumor drug, suggesting that there is 
a great need to seek means of decreasing SB’s tox-
icity while retaining or augmenting its useful phar-
macological effects.
In summary, SB was shown here to have toxicity 
in the mouse heart and liver and its NOAEL in this 
animal model was less than 5 mg/kg/day for 1 week 
and 0.25 mg/kg/day for 8 weeks.
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